Amitriptyline
Adverse Effect: Amitriptyline toxicity (dry mouth, blurred vision, urinary retention, sedation) Clinical Management: Monitor patients for signs of Amitriptyline toxicity (dry mouth, urinary retention, sedation) with concomitant therapy with propafenone. Amitriptyline serum levels might be considered in some clinical situations.
Chlordiazepoxide
Adverse Effect: chlordiazepoxide toxicity (dry mouth, blurred vision, urinary retention, sedation) Clinical Management: Monitor patients for signs of Chlordiazepoxide (dry mouth, urinary retention, sedation) concomitant with propafenone therapy. Chlordiazepoxide serum levels might be considered in some clinical situations.
Clomipramine
Adverse Effect: Clomipramine toxicity (dry mouth, sedation) Clinical Management: Monitor patients for signs of Clomipramine toxicity with concomitant therapy with propafenone. Clomipramine serum levels might be considered in some clinical situations.
Digoxin
Adverse Effect: digoxin toxicity (nausea, vomiting, cardiac arrhythmias) Clinical Management: Monitor digoxin levels 48 to 96 hours after discontinuing or adding propafenone to digoxin therapy. In addition, monitor digoxin levels when doses of propafenone are increased.
Doxepin
Adverse Effect: Doxepin toxicity (sedation, dry mouth) Clinical Management: Monitor for symptoms of Doxepin toxicity.
Fluoxetine
Adverse Effect: Increased serum propafenone concentrations Clinical Management: Monitoring of propafenone levels may be necessary to avoid potential toxicity.
Imipramine
Adverse Effect: Imipramine toxicity (dry mouth, sedation) Clinical Management: Monitor patients for signs of Imipramine toxicity with concomitant therapy with propafenone. Imipramine serum levels might be considered in some clinical situations.
Lignocaine
Adverse Effect: Potentiation of adverse central nervous system effects (dizziness, paresthesia, lethargy) Clinical Management: Patients should be monitored for unpleasant central nervous system adverse effects when given propafenone and lidocaine concurrently, including lightheadedness, paresthesia, lethargy, and somnolence.
Metoprolol
Adverse Effect: metoprolol toxicity (bradycardia, fatigue, shortness of breath) Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly blood pressure. A dosage adjustment for the Propafenone may be required.
Nortriptyline
Adverse Effect: Nortriptyline toxicity (dry mouth, blurred vision, urinary retention, sedation) Clinical Management: Monitor patients for signs of Nortriptyline toxicity with concomitant therapy with propafenone. Nortriptyline serum levels might be considered in some clinical situations.
Propranolol
Adverse Effect: an increased risk of propranolol toxicity (fatigue, bradycardia, hypotension) Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly blood pressure. A dosage adjustment for the Propranolol may be required.
Quinidine
Adverse Effect: propafenone toxicity (blurred vision, CNS depression, tachycardia) Clinical Management: If concurrent therapy is required, monitor cardiac function carefully. A dosage adjustment for propafenone may be required.
Rifampicin
Adverse Effect: Decreased propafenone effectiveness Clinical Management: Rifampin and propafenone should not be used concurrently unless the ability to monitor propafenone plasma concentrations is available for dosage adjustment.
Sertraline
Adverse Effect: An increased risk of propafenone toxicity (cardiac arrhythmias) Clinical Management: Coadministration of these agents should be approached with caution. Monitor the EKG in patients receiving concurrent propafenone and sertraline. Doses of propafenone may need to be reduced.
Theophylline
Adverse Effect: Theophylline toxicity (nausea, vomiting, palpitations, seizures) Clinical Management: Theophylline serum concentrations should be closely monitored when propafenone is added, discontinued, or when dosing changes occur. Dosing adjustments of theophylline may be necessary.
Trimipramine
Adverse Effect: Trimipramine toxicity (dry mouth, blurred vision, urinary retention, sedation) Clinical Management: Monitor patients for signs of Trimipramine toxicity with concomitant therapy with propafenone. Trimipramine serum levels might be considered in some clinical situations.
Warfarin
Adverse Effect: An increased risk of bleeding Clinical Management: In patients receiving oral anticoagulant therapy with warfarin, the prothrombin time ratio or international normalized ratio (INR) should be closely monitored with the addition or withdrawal of propafenone. The stability of the anticoagulant response should also be periodically reassessed during concurrent therapy. Adjustment of the warfarin dosage may be required |